NCT04791384View on ClinicalTrials.gov

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 21, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

January 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

Abemaciclib

taken orally

DRUG

Elacestrant

taken orally

Trial Locations (3)

27710

RECRUITING

Duke Cancer Center, Durham

80045

RECRUITING

University of Colorado, Aurora

99216

RECRUITING

Cancer Care Northwest, Spokane Valley

Sponsors

Lead Sponsor

Criterium, Inc.
All Listed Sponsors
lead

Criterium, Inc.

INDUSTRY

NCT04791384 - Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer | Biotech Hunter | Biotech Hunter